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2ABSTRACT
Background 
Hypertension is the most common risk factor for cardiovascular disease worldwide. However, 
the optimal systolic intensification threshold, time to medication intensification after the first 
elevated blood pressure measurement, and time to blood pressure follow-up after medication 
intensification in the management of hypertension are not well established.
Objective
I sought to determine the systolic intensification threshold, time-to-intensification and time-to-
follow-up associated with the lowest risk of cardiovascular events or death in a population of 
primary care patients with hypertension.
Methods
A retrospective cohort study of 88,756 patients with hypertension from The Health Improvement 
Network database was performed. The systolic intensification threshold, time-to-intensification 
and time-to-follow-up were established over a 10-year assessment period, and analyzed with 
respect to subsequent risk of acute cardiovascular event or death. The Cox survival model was 
adjusted for age, sex, smoking status, socioeconomic deprivation, history of diabetes, 
cardiovascular disease or chronic kidney disease, Charlson Comorbidity Index, body mass index, 
medication possession ratio, and baseline blood pressure elevation.
Results
During a median follow-up of 37.4 months after the treatment strategy assessment period, 9,985 
participants experienced acute cardiovascular event or death (11.3%). Systolic intensification 
thresholds of 130-150 mmHg were associated with no difference in risk, while thresholds greater 
than 150 mmHg were associated with progressively greater risk. Outcome risk increased 
progressively from the lowest (0-1.4 months) to the highest quintile of time to medication 
3intensification. The highest quintile of time to-follow-up (>2.7 months) was also associated with 
increased outcome risk.
Conclusions
Systolic intensification threshold higher than 150 mmHg, delays of greater than 1.4 months 
before medication intensification following systolic blood pressure elevation, and delays of 
greater than 2.7 months before blood pressure follow-up following antihypertensive medication 
intensification were associated with increased risk for acute cardiovascular events or death.
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5GLOSSARY OF ABBREVIATIONS
BMI Body mass index
CCI Charlson comorbidity index
CAD Coronary artery disease
CHF Congestive heart failure
CKD Chronic kidney disease
COPD Chronic obstructive pulmonary disease
CVA Cerebrovascular accident
DM Diabetes mellitus
ESH/ESC European Society of Hypertension / European Society of Cardiology
JNC Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure
NICE National Institute for Health and Care Excellence
PVD Peripheral vascular disease
SBP Systolic blood pressure
THIN The Health Improvement Network
UK  United Kingdom
6INTRODUCTION
Elevated blood pressure is the single most common risk factor for cardiovascular 
morbidity and mortality worldwide, and the lowering of blood pressure through medical 
treatment mitigates this risk. Hypertension is the most commonly diagnosed outpatient condition 
among non-pregnant adults in the United States and United Kingdom. Hypertension management 
is among the most common reasons for outpatient physician visits, and the medical treatment of 
hypertension is the most common reason for chronic medication prescriptions
2-5. However, many 
key aspects of optimal medical management for hypertension remain unclear. 
Definition of Hypertension
Higher blood pressure is correlated with increased risk of risk stroke, myocardial 
infarction, heart failure, renal disease, and mortality in a continuous manner well into the 
normotensive range, though very low blood pressures may also confer increased risk.
6-9 The 
definition of hypertension is therefore somewhat arbitrary, but is necessary to guide patient 
assessment and management. In actual practice, patients with systolic blood pressure above 140 
mmHg are routinely diagnosed with hypertension based on several sets of recent guidelines, and 
the existence of this diagnosis encourages providers to treat patients until systolic blood pressure 
falls below 140 mmHg. Nonetheless, the original systolic threshold for hypertension was defined 
using observational data (rather than treatment data) associating higher blood pressure with 
cardiovascular risk, and the evidence that medically treating patients with stage 1 systolic 
hypertension improves outcomes is limited.
14 
Systolic Blood Pressure Treatment Threshold: Current Guidelines and State of the Literature
7Major society guidelines differ substantially in their recommendations for the 
management of patients with stage 1 systolic hypertension. While the JNC 8 and ESH/ESC 
guidelines suggest a goal SBP of <140 mmHg for younger patients and <150 mmHg for older 
patients, they differ with regard to the age at which treatment may be liberalized. On the other 
hand, the NICE guidelines recommend treating patients with SBP <160 mmHg only when other 
cardiovascular risk factors or end-organ damage are present,
4 and a Cochrane review found no 
clear evidence of benefit in pharmacotherapy for mild hypertension without considering pre-
existing diabetes or end organ damage.
17 These disagreements are also reflected in guidelines 
issued by other international societies, and reflect difficulties in weighing the available evidence 
in the absence of definitive data.
10
There is no clinical trial that has adequately examined the question of whether medical 
treatment of grade 1 systolic hypertension (140-159 mmHg) leads to improved outcomes; the 
question of whether treating patients with systolic blood pressure between 140-149 mmHg 
confers clinical benefit is particularly controversial. Several large randomized trials including 
FEVER, MRC, and HDFP have shown cardiovascular benefit when reducing blood pressure 
below 140 mmHg, but all included patients with initial blood pressure above 150 mmHg. Other 
issues that limit the generalizability of available randomized clinical trials include the paucity of 
direct comparisons between blood pressure targets, incongruity of patient populations 
(differences in age, previous cardiovascular history, and other comorbidities), and the difficulty 
of achieving sufficient power to detect differences at various thresholds.
Time-to-intensification and Follow-up after Intensification
Among all patients there is little available evidence to guide the optimal time interval 
between measurement of elevated blood pressure and antihypertensive medication 
8intensification, or between medication intensification and follow-up measurement of blood 
pressure. This is particularly important because routine clinical practice differs from clinical 
trials in that substantial delays may exist between the observation of an elevated blood pressure 
and medication intensification or between medication intensification and follow-up measurement 
of blood pressure, but the impact of such delays on patient outcomes is not well understood.
The current ESH/ESC and previous JNC 7 management guidelines suggest follow-up 
after antihypertensive treatment intensification within 2-4 weeks or 1 month, respectively, but 
these recommendations are primarily based on expert opinion rather than clinical data. The 
recent JNC 8 guidelines do not suggest a particular interval for blood pressure assessment, but 
recommend—based on expert opinion—intensifying treatment within a month if goal blood 
pressure is not attained on the current treatment.
11
Although direct clinical evidence in support of these recommendations is limited, 
previous studies have examined the relationship between visit frequency and hypertension 
management. Increased encounter frequency has been associated with improved intermediate 
outcomes such as increased incidence of blood pressure control and more rapid blood pressure 
control.
24-26 There is also evidence that providers often delay intensifying antihypertensive 
therapy when treatment goals are not met, and that more frequent intensification of 
antihypertensive therapy leads to better blood pressure control. In addition, several studies have 
suggested that delays in blood pressure control lead to increased outcome risk. The VALUE trial 
initially achieved greater blood pressure reductions in the amlodipine group compared to the 
valsartan group, and a transient difference in the incidence of stroke was observed while this 
difference persisted.
28 In an open-label extension of the Syst-Eur trial, patients who were 
immediately randomized to the treatment arm had lower risk for stroke and cardiovascular 
complication, compared to those who received delayed treatment in the extension phase.
29
9Study Objective
I conducted a retrospective cohort study to establish the systolic intensification threshold, 
time-to-intensification and time-to-follow-up that are associated with the lowest risk of 
cardiovascular events or death in a large population of primary care patients with hypertension.
METHODS
Data Source
The Health Improvement Network (THIN) is an electronic medical record database 
containing patient encounter data collected from primary care practices throughout the United 
Kingdom that choose to submit their electronic records for research purposes. Patient and 
practice characteristics within the THIN database are representative of those within the general 
UK primary care population.
30 General practitioners are required to document patient encounters 
via a process that is subject to audit, and the accuracy of patient records is linked with 
compensation via the UK Quality and Outcomes Framework. Patient mortality and death dates in 
THIN are assessed using information which is forwarded to the patient’s general practitioner 
upon administration of the death certificate. The accuracy of diagnosis and death records in the 
THIN database have been previously validated.
Study Cohort
Adults registered in primary care practices in the THIN database between 1986 and 2010 
were studied. I included all patients who were 18 years or older, had at least one diagnosis code 
associated with hypertension (Table S1), had at least one blood pressure measurement and at 
least one antihypertensive medication initiated or intensified, had at least 10 years of continuous 
10data (to allow adequate time to assess treatment strategy), and had at least one set of height and 
weight data. To permit adjustment for socioeconomic deprivation, patients with missing postal 
codes were excluded. I also excluded patients with BMI less than 15 or greater than 100 to 
minimize the effect of implausible values.
This study was approved by the Partners HealthCare System institutional review board. A 
waiver was obtained for the requirement of written informed consent.
Study Measurements
Baseline patient characteristics and pre-existing medical conditions were assessed during 
the run-in period.
33  The run-in period began on the clinic registration date and ended on the 
latter date of 1) twelve months after clinic registration or 2) the first documentation of a 
hypertension-related diagnosis code or systolic blood pressure (SBP) greater than or equal to 130 
mmHg.
A treatment strategy assessment period was defined for each patient, which consisted of 
the first 10 years following the end of the run-in period. This approach allowed us to represent 
the patient's treatment as a single summary as is the standard approach in cohort studies.
34 
During the treatment strategy assessment period, the minimum intensification threshold 
was defined as the lowest SBP at which antihypertensive medication intensification occurred 
(over the set of all known intensification events), rounded down to the nearest 10 mmHg. 
Antihypertensive medication intensifications were defined as the initiation of a new 
antihypertensive (complete medication list in Table S2), or an increase in the daily dose of an 
existing antihypertensive, on a date on which blood pressure was measured.
35 Medication 
adjustments performed when SBP was already lower than 130 mmHg are unlikely to represent 
antihypertensive medication intensifications and were therefore excluded from the analysis.
11Time-to-intensification was defined as the mean length of unintensified hypertensive 
periods; each hypertensive period started on the day when SBP was first measured to be above 
the minimum intensification threshold and ended on the first subsequent day when medications 
were intensified, or when the unintensified period was censored (e.g. SBP fell below the 
threshold). Transient hypertensive periods, defined by a single elevated blood pressure 
measurement above the intensification threshold that fell below the threshold at the next blood 
pressure reading in the absence of medication intensification, were excluded from the analysis.
Time-to-follow-up was defined as the mean time between each medication intensification 
and the next visit at which blood pressure was recorded.
Time to outcome was defined as the time elapsed between the end of the treatment 
strategy assessment period and the composite outcome, which was defined as first acute 
cardiovascular event (myocardial infarction, cerebrovascular accident, acute congestive heart 
failure episode or peripheral vascular disease) or death (Table S3).  The overall relationship 
between the run-in, treatment strategy assessment and outcome assessment periods is illustrated 
in Figure 1. 
Age was calculated at the conclusion of the run-in period. BMI was calculated using the 
first set of height and weight data available for each patient. Smoking history was defined as past 
or current tobacco use. Chronic kidney disease was defined as the presence of a diagnosis code 
associated with CKD (except stage 1 or 2 CKD) or an estimated glomerular filtration rate less 
than 60 mL/min/1.73 m
2 based on the Chronic Kidney Disease Epidemiology Collaboration 
(CKD-EPI) equation (Table S3).
36 Medication possession ratio (as a proxy for compliance) was 
calculated for each patient as a weighted average of the number of days’ supply actually 
prescribed for each medication, divided by the total period of time over which that medication 
was prescribed.
37 The Charlson comorbidity index (CCI) was calculated from the Read code list 
12using a previously described and validated method while excluding conditions individually 
included in the multivariable analysis.
38
Socioeconomic status was estimated using the Townsend socioeconomic deprivation 
score, which is calculated using economic and demographic data based on the patient’s postal 
code.
39 Patients who had multiple addresses during the follow-up period had their Townsend 
deprivation score calculated as a weighted average based on time spent living at each address.
Statistical Analysis
Summary statistics were produced using frequencies and proportions for categorical 
variables, and means, standard deviations, medians and ranges for continuous variables.
A Cox proportional hazards regression model was used to compare event-free survival 
for patients with various treatment strategies as defined by systolic intensification threshold, 
time-to-intensification and time-to-follow-up.
40 The analysis was stratified by entry age category 
(<60, 60-75, >75) and also adjusted for sex, smoking status, Townsend score, past history of 
diabetes/cardiovascular disease/chronic kidney disease, Charlson comorbidity index, body mass 
index, medication possession ratio, and the mean difference by which SBP exceeded the 
minimum intensification threshold at the beginning of each hypertensive period.
43
I anticipated that time-to-intensification and time-to-follow-up may have a nonlinear 
relationship with respect to event risk, with an optimal range of values and increased hazards 
outside this range. On the other hand, thresholds defined by quintiles of each variable are 
somewhat arbitrary, with the boundaries determined by physician behavior in our particular 
sample. To provide an alternative view of the relationship between time-to-intensification, time-
to-follow-up and event risk, I constructed Cox regression models which included time-to-
intensification and time-to-follow-up as natural cubic splines to account for a continuous 
13nonlinear functional dependence between these treatment parameters and the log hazard rate.
44 
Spline knots were placed at the 5th, 25th, 75th and 95th percentiles of the overall distribution for 
time to intensification and time to follow-up. These models were stratified by entry age and 
adjusted for smoking status, socioeconomic deprivation, history of cardiovascular 
disease/diabetes/chronic kidney disease, and Charlson comorbidity index. 
P-values were obtained using the type III test, and significance thresholds were adjusted 
for multiple hypothesis testing using the Simes-Hochberg method. All analyses were performed 
using SAS version 9.3 (SAS Institute, Inc, Cary, NC).
RESULTS
Patient Characteristics
I identified 148,930 patients from the THIN database with a hypertension diagnosis code 
and at least 10 years of subsequent primary care records between 1986 and 2010. I excluded 
patients who had no blood pressure measurements, were under 18 years, had fewer than 10 years 
of follow-up, had no medication intensifications during the 10 years following hypertension 
diagnosis, had missing demographic data, or implausible BMI values (Figure S1). The final 
study population therefore consisted of 88,756 adult patients.
Baseline patient characteristics are shown in Table 1. Following the treatment strategy 
assessment period, mean follow-up time was 37.4 months; 11.3% of patients experienced an 
acute cardiovascular event or death. 
Treatment Strategy and Outcome Risk
In the multivariable analysis, male gender, older age, obesity, diabetes, previous 
cardiovascular disease, chronic kidney disease, history of smoking, increased Charlson 
14comorbidity index and socioeconomic deprivation were associated with greater risk for 
cardiovascular events or death (Table 3).  SBP intensification thresholds of 160 mmHg or higher 
were also associated with progressively increased risk for the composite outcome (Table 2). 
Systolic intensification thresholds lower than 150 mmHg weakly trended towards further 
decreased composite outcome risk, but the difference did not reach statistical significance.
The lowest quintile of time to medication intensification (0-1.4 months) was associated 
with the lowest risk for the composite outcome, and higher quintiles were associated with 
progressively greater risk. Compared to patients who received blood pressure follow-up within 
0-2.7 months (quintiles 1-4), patients who had time-to-follow-up greater than 2.7 months also 
had increased risk for the composite outcome. 
To examine the relationship between prescribing behavior and event rate without 
dividing follow-up and intensification time into discrete categories, a natural cubic spline model 
was created (Figure 2).  Shorter times to medication intensification were associated with 
decreased risk of cardiovascular event or death, with the greatest rate of risk increase occurring 
within the first 9 months. A J-shaped curve was noted for time-to-follow-up, as both very short 
and very long follow-up times were associated with increased risk of cardiovascular event or 
death.
A secondary analysis was performed using all-cause mortality as the endpoint. In this 
analysis a similar relationship was found between systolic intensification threshold, time-to-
intensification, time-to-follow-up and all-cause mortality (Table S4). Higher quintiles of time-to-
intensification were associated with progressively increased overall mortality risk, as were time-
to-follow-up after intensification greater than 2.7 months and systolic intensification thresholds 
of greater than 150 mmHg.
15Sensitivity Analysis
To investigate whether defining a shorter treatment strategy assessment period would 
lead to misclassification of prescribing strategies, we attempted to define a 5-year treatment 
strategy assessment period for the study population. With this approach, 33.5% of all patients in 
the highest quintile for time-to-intensification (when using the 10-year treatment strategy 
assessment period) were reclassified to lower quintiles. The fraction of unintensified periods in 
the highest quartile which were censored also decreased with increasing length of the treatment 
strategy assessment period (Figure S2). 
Nonetheless, we examined the effect that alternative inclusion criteria would have on the 
optimal intensification threshold. To this end, we conducted an alternative analysis in which a 3-
year period was used to assess the medication intensification strategy (instead of 10 years). Since 
66.6% of these patients did not have any medication intensifications during the first 3 years, 
time-to-intensification and time-to-follow-up after intensification were not defined. For patients 
without intensifications, we assumed that the highest blood pressure attained remained below the 
intensification threshold. For such patients we therefore defined the estimated systolic 
intensification threshold as the highest attained non-transient blood pressure during the treatment 
strategy assessment period, rounded up to the nearest 10mmHg. Under these liberalized inclusion 
criteria, 329,491 patients were identified. In this analysis, intensification thresholds >150 mmHg 
remained associated with increased risk for cardiovascular events or death (Table S5). Notably, 
in this model intensification thresholds of 150 mmHg or lower were associated with 
progressively decreased risk, down to a minimum intensification threshold of 130 mmHg. 
Strategy Changes after Acute Cardiovascular Events
16To investigate whether physician prescribing behavior changes after an acute 
cardiovascular event, we calculated minimum systolic intensification thresholds for the 7,578 
patients who had an acute cardiovascular event during the treatment strategy assessment period. 
Among these patients, treatment became more aggressive after an acute cardiovascular event 
(mean minimum systolic intensification threshold 161 mmHg vs 154 mmHg, p < 0.0001). This 
was true even among patients for whom this event was not their first acute cardiovascular event 
(mean minimum systolic intensification threshold 160 mmHg vs 154 mmHg, p < 0.0001).
In the event that physicians decide to alter their hypertension management strategy after 
the patient experiences an acute cardiovascular event, the current approach raises a risk of 
misrepresenting treatment strategies when there are risk factors present (e.g. acute cardiovascular 
events) that are at the same time determined by previous exposure (e.g. hypertension control) and 
themselves alter the subsequent treatment strategy.
47 To estimate the effect that acute 
cardiovascular events during the treatment strategy assessment period may have on our model, I 
included a variable corresponding to the presence of such an event during this period. Although 
any acute cardiovascular event during the treatment strategy assessment period was strongly 
correlated with risk for subsequent events (HR 1.918, 95% CI 1.821-2.021), the inclusion or 
exclusion of this variable did not alter either the direction or significance of hazard differences 
between treatment strategies.
Visit Frequency
To investigate whether time-to-intensification and time-to-follow-up have an effect on 
outcomes independent of visit frequency, I introduced a variable corresponding to the total 
number of blood pressure measurements over the 10-year treatment strategy assessment period. 
The inclusion of this variable did not qualitatively change the significance or direction of the 
17previously observed interquintile risk differences in time-to-intensification or time-to-follow-up. 
Increased visit frequency was associated with increased composite outcome risk after adjustment 
for time-to-intensification and time-to-follow-up (HR 1.003 per visit, 95% CI 1.001-1.004, p < 
0.0001), but not before (HR 1.001, 95% CI 1.000-1.003, p = 0.065).
DISCUSSION
In this large retrospective study, I examined the relationship between several process 
measures of treatment of elevated blood pressure and risk of cardiovascular events or death. I 
found that systolic intensification thresholds higher than 150 mmHg and delays of greater than 
1.4 months before medication intensification following SBP elevation above the intensification 
threshold were associated with increased risk for acute cardiovascular event or death. After each 
antihypertensive medication intensification, lack of blood pressure follow-up within 2.7 months 
was also associated with increased risk for the composite outcome.
I observed that a systolic treatment target greater than 150 mmHg was associated with 
greater risk for acute cardiovascular event or death, when compared to SBP targets of 150 mmHg 
or lower. These results are broadly consistent with the extant evidence from available clinical 
trials. In the main model, there was a weak trend towards improved outcomes at even lower 
intensification thresholds. When the inclusion criteria were liberalized in a sensitivity analysis to 
include all patients with three or more years of data whether or not their treatment was 
intensified, significant progressive decrease in risk was seen down to the lowest threshold of 130 
mmHg. This raises the possibility that more aggressive intensification thresholds have a small 
added benefit that could be better characterized with an even larger dataset.
A “J-curve” corresponding to increased outcome risk at low blood pressure has 
previously been reported in observational studies for diastolic and occasionally systolic
7-9 blood 
18pressure, but I did not detect this phenomenon. Notably in our study I examined SBP targets, 
whereas previous studies that noted the systolic J-curve analyzed mean blood pressures without 
regard for treatment which may be more vulnerable to confounding from baseline patient illness. 
On the other hand, it remains possible that systolic treatment thresholds even lower than 130 
mmHg, which was the lowest treatment target I examined, may be associated with increased 
cardiovascular risk.
In this study, I demonstrate that two process measures of blood pressure management that 
are directly related to encounter frequency - the time to medication intensification and the time to 
follow-up after intensification - are independent predictors of risk for cardiovascular mortality or 
death. This is, to our knowledge, the first study that has directly examined the effect of these 
variables on patient outcomes. In our study population, the majority of patients had blood 
pressure follow-up within 2.7 months after each medication intensification, which was the time 
period associated with lowest risk for the composite outcome. However, the majority of patients 
did not receive medication intensification within 1.4 months. Further investigation is needed to 
determine whether interventions to reduce the time to medication intensification would improve 
outcomes.
Limitations
There are several significant limitations to this study. I assumed that providers intensify 
antihypertensive treatment until the goal blood pressure is reached, and therefore used the 
minimum intensification threshold as a proxy for goal blood pressure. Patients with hypertension 
resistant to treatment may never reach the provider’s intended treatment goal, leading to potential 
overestimation of the systolic treatment threshold. However this would be expected to bias the 
results towards the null hypothesis, e.g. if some treatment thresholds are overestimated, then the 
19optimal systolic interpretation threshold may be even lower than 150 mmHg. As aforementioned, 
this possibility is supported by the small improvements in outcome observed at lower 
intensification thresholds under some sensitivity analyses (Table S5).
There is controversy surrounding the optimum systolic treatment threshold for patients 
with diabetes, chronic kidney disease, atherosclerosis, or advanced age, but our sample size was 
insufficiently large to permit stratification by these subgroups. Although I examined the effects 
of treatment on outcome, and our treatment strategy assessment period chronologically preceded 
the outcome assessment period, the retrospective nature of our data limits our ability to make 
causal inferences. Our study was limited to patients who had regular access to primary care, and 
who had hypertension diagnosed by a general practitioner. However, approximately 99% of 
residents of the United Kingdom are registered with a general practitioner, so the potential for 
patient selection bias is less than it would be in many other countries.
49
The use of certain anti-hypertensive medications (for instance angiotensin converting 
enzyme inhibitors and beta blockers) may have effects on cardiovascular outcome that are 
independent of their effect on blood pressure. In this study I assumed that all new 
antihypertensive medications prescribed for a patient with elevated blood pressure represented 
hypertension treatment intensifications, and was not able to account for dual indications which 
might compel a physician to select one class of anti-hypertensive instead of another.
In the natural cubic spline model (Figure 2), there is a visual trend towards higher hazards 
when patients had very quick blood pressure follow-up, though this did not reach statistical 
significance in the multivariable model. This is likely due to confounding by indication, since I 
was unable to distinguish scheduled appointments from urgent care visits. Patients with a blood 
pressure check immediately following a previous appointment may have been seen for other 
urgent indications, which may itself be associated with an apparent increase in outcome risk. If 
20urgent care visits were eliminated, it is possible that further benefits may be seen at follow-up 
intervals shorter than 2.7 months.
In this study, outcomes after hypertension treatment were evaluated by defining separate 
time periods for the assessment of treatment strategy and outcomes. This was done to reduce the 
time-dependent confounding caused by variations in blood pressure level, which predicts 
antihypertensive treatment, is itself influenced by treatment, and also affects outcome risk
52. A 
concurrent treatment strategy assessment and outcome assessment period would also introduce 
an undesirable bias towards systematically shorter treatment strategy assessment periods for 
patients who have outcomes early in the study, resulting in systematic overestimation of 
treatment thresholds for patients with early cardiovascular events. I chose a 10-year treatment 
strategy assessment period because I found that shorter treatment strategy assessment periods are 
vulnerable to misclassification of time-to-intensification, since the assessment period may end 
before intensification occurs. Strategies corresponding to longer time-to-intensification and 
longer follow-up times would be disproportionally affected, which would lead to systematic 
censoring bias. This study design necessarily limits our analysis to patients who had 10 years of 
treatment data available past the hypertension diagnosis date (e.g. the length of the strategy 
assessment period). However, considering that mean life expectancy at age 65 in the United 
Kingdom is now over 17 years for men and 20 years for women, this may be a good initial 
approximation for patients in industrialized societies with routine access to medical care.
53
Future Investigations
Marginal structural models are statistical constructs designed to address biases which are 
introduced when studying time-varying exposures (such as hypertension) which predict both 
21outcome risk and subsequent treatment. The use of a marginal structural model to confirm this 
analysis would have several potential benefits. 
A marginal structural model would allow variations in blood pressure treatment for a 
given patient could be better taken into account, instead of the current approach which assumes a 
static blood pressure goal over the duration of the study period. This would reduce the need to 
define chronologically separate periods for the assessment of treatment and outcome, and would 
better reflect reality since blood pressure treatment is generally continuous until an acute event 
occurs (and also continues past the time of an acute cardiovascular event). When adjusting for an 
intermediate variable that is also a confounder—e.g. the degree of blood pressure elevation 
during the treatment period—standard regression models (such as the one used in this study) tend 
to block the indirect effect that previous hypertension treatment has on subsequent 
cardiovascular risk, whereas marginal structural models are less vulnerable to this bias.
55 Finally, 
my current model is potentially vulnerable to non-random censoring, in which patients who are 
lost to follow-up (e.g. censored) may also be more likely to have uncontrolled hypertension 
and/or have adverse outcomes. Although I mitigate this bias by adjusting for measures of 
compliance (medication possession ratio and visit frequency in the sensitivity analysis), inverse 
probability weighting as applied through a marginal structural model can simulate a pseudo-
population in which all participants complete follow-up, and thereby attain a more accurate 
estimate of the treatment effect.
56
Notably, each of the aforementioned biases would be expected to bias the results towards 
the null hypothesis by decreasing the apparent difference in hazard between treatment strategies. 
Therefore these limitations are somewhat mitigated by the large sample size, though it remains 
possible that the actual effect size is stronger than what I observed.
22Although I considered implementing a marginal structural model for the current analysis, 
the approach is limited by the computational complexity of having multiple treatment 
parameters: intensification threshold, time-to-intensification, and time-to-follow-up, if 
implemented simultaneously, would generate a potential total of 6 x 5 x 5 = 150 treatment arms. 
In a future investigation, a marginal structural model that asks a more limited clinical question 
(e.g. short vs long follow-up time) may be helpful in verifying the results of the current study.
The strongest level of clinical evidence is a randomized controlled trial, which inherently 
balances treatment arms along both known and unknown variables and avoids the risk for 
allocation bias inherent in retrospective studies.
57 While there are inherent challenges to studying 
compliance-related variables in a clinical trial, one possible design would be to perform a 
randomized intervention study to measure differences in cardiovascular risk in a patient 
population known to have poor prior rates of timely blood pressure treatment and follow-up.
58
SUMMARY
The optimal medical management of hypertension remains highly controversial. Despite 
the high prevalence of stage 1 hypertension, the JNC 8, ESH/ESC and NICE guidelines (among 
others) differ substantially in their recommendations for systolic treatment targets, how quickly 
patients with elevated blood pressure should be intensified, and how quickly patients should be 
followed up after antihypertensive treatment intensification.
In this retrospective cohort study, I find that systolic blood pressure target, time-to-
intensification and time-to-follow-up are predictors of increased risk for acute cardiovascular 
events or death. I observe an increase in risk of cardiovascular events or death associated with 
systolic targets greater than 150 mmHg, delays of greater than 1.4 months before medication 
intensification or delays of greater than 2.7 months before blood pressure follow-up after 
23medication intensification. This is, to my knowledge, the first large study that specifically 
examines the effect of antihypertensive medication time-to-intensification and time-to-follow-up 
on patient outcomes. In patients with hypertension and regular access to primary care, timely 
achievement of blood pressure targets and regular follow-up may be an important factor in 
minimizing overall risk of cardiovascular events or death.
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FIGURES 
 
 
Figure 1: 
Design of study periods for evaluation of treatment strategy and outcome. 
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Figure 2:  
Effects of time to antihypertensive intensification and time-to-follow-up after intensification on 
risk of acute cardiovascular event or death. 
In panel A), the hazard ratio for acute cardiovascular event or death is shown in relation to the 
mean months elapsed between systolic blood pressure elevation above the minimum 
intensification threshold, and either antihypertensive medication intensification or censoring of 
the unintensified period (via spontaneous normalization of blood pressure). 
In panel B), the hazard ratio for acute cardiovascular event or death is shown in relation to the 
mean months elapsed between each antihypertensive medication intensification, and the next 
blood pressure measurement.  
Solid lines indicate hazard ratios, and dashed lines indicate 95% confidence intervals calculated 
using natural cubic spline regression. Reference points are placed at the means of the respective 
distributions for time-to-intensification and time-to-follow-up. Knots are placed at the 5th, 25th, 
75th and 95th percentiles of each variable. The multivariable model is adjusted for age, sex, body 
mass index, smoking status, socioeconomic deprivation, history of cardiovascular disease, 
chronic kidney disease or diabetes, other chronic medical conditions as represented by the 
Charlson comorbidity index, minimum systolic intensification threshold, mean initial blood 
pressure elevation above the intensification threshold, and medication possession ratio. 
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TABLES 
 
Table 1:  
Baseline characteristics of study patients. 
Characteristic   
Number of participants  88756
Age, mean (SD)  58.5 (11.9)
Men (%)  36800 (41.5)
BMI, mean (SD)  27.6 (5.0)
Past/current smoker (%)  50176 (56.5)
History of any cardiovascular disease (%)  9907 (11.2)
   History of coronary artery disease (%)  6827 (7.7)
   History of congestive heart disease (%)  601 (0.7)
   History of stroke (%)  2450 (2.8)
   History of peripheral vascular disease (%)  981 (1.2)
History of diabetes (%)  5863 (6.6)
History of chronic kidney disease (%)  2420 (2.7)
Modified Charlson index, mean (SD)  0.27 (0.6)
Townsend deprivation score, mean (SD)  2.66 (1.3)
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Table 2:  
Characteristics of the Treatment Strategy Assessment Period. 
P-values in italics are not significant after Simes-Hochberg adjustment for multiple hypothesis 
testing. Mean SBP elevation over intensification threshold denotes mean difference between 
actual blood pressure and systolic intensification threshold at the beginning of each hypertensive 
period. 
 
Characteristic 
n (%) or 
mean (SD)
   
Hazard 
Ratio     p-value     95% CI 
Minimum systolic intensification 
threshold, mmHg       
   130-139  12229 (13.8) 0.984 0.69  0.908-1.066 
   140-149  20458 (23.0) 1.000 --  --
   150-159  21329 (24.0) 1.033 0.34  0.966-1.103 
   160-169  17513 (19.7) 1.211 <0.0001  1.127-1.300 
   170-179  8978 (10.1) 1.424 <0.0001  1.306-1.554 
   180+  8249 (9.3) 1.688 <0.0001  1.549-1.839 
Mean time to intensification, 
quintiles, months         
   0-1.439  17752 (20.0) 1.000 --  --
   1.440-4.681  17751 (20.0) 1.119 0.0009  1.047-1.196 
   4.682-8.689  17749 (20.0) 1.229 <0.0001  1.148-1.315 
   8.690-15.320  17753 (20.0) 1.193 <0.0001  1.111-1.281 
   15.321+  17751 (20.0) 1.254 <0.0001  1.166-1.349 
Mean time to follow-up after 
intensification, quintiles, months       
   0-0.723  18283 (20.6) 1.058 0.085  0.992-1.128
   0.724-1.018  17524 (19.7) 1.000 --  --
   1.019-1.544  17887 (20.2) 1.013 0.71  0.949-1.079 
   1.545-2.727  17537 (19.8) 1.066 0.050  1.000-1.137 
   2.727+  17525 (19.7) 1.178 <0.0001  1.108-1.253 
Mean SBP elevation over 
intensification threshold, mmHg (%)       
   1-9  47173 (53.1) 1.000 --  --
   10-19  31376 (35.4) 1.128 <0.0001  1.068-1.191 
   20-29  8514 (9.6) 1.375 <0.0001  1.271-1.488 
   30-39  1508 (1.7) 1.505 <0.0001  1.308-1.731 
   40-49  185 (0.2) 1.777 0.0010  1.263-2.501 
        
Medication possession ratio  0.859 (0.19) 0.798 <0.0001  0.728-0.876
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Table 3:  
 
Effects of baseline patient characteristics on the risk of acute cardiovascular event or death. 
Age categories are calculated at the beginning of the outcome assessment period. History of 
cardiovascular disease and diabetes were omitted from the calculation of the modified Charlson 
index. Hazard ratio for Townsend deprivation score is per quintile increase in socioeconomic 
deprivation. Hazard ratio for the modified Charlson comorbidity index is per one point increase 
in the Charlson score. 
 
Variable  Hazard ratio 95% CI p-value 
Female gender  0.736 0.705-0.767 <0.0001 
Age     
   <60  1.000 -- -- 
   60-74  2.369 2.188-2.565 <0.0001 
   75+  5.993 2.537-6.486 <0.0001 
Townsend deprivation score  1.094 1.079-1.111 <0.0001 
Past or current smoker  1.212 1.162-1.265 <0.0001 
Modified Charlson comorbidity index  1.138 1.108-1.167 <0.0001 
BMI     
   <20  1.949 1.659-2.289 <0.0001 
   20-24.9  1 -- -- 
   25-29.9  0.974 0.930-1.020 0.27 
   30+  1.079 1.022-1.139 0.0058 
Preexisting medical conditions     
   Diabetes  1.616 1.511-1.729 <0.0001 
   CAD  1.481 1.398-1.570 <0.0001 
   CHF  1.607 1.379-1.871 <0.0001 
   CVA  1.445 1.322-1.774 <0.0001 
   PVD  1.596 1.435-1.729 <0.0001 
Chronic kidney disease  1.151 1.021-1.298 0.021 
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SUPPLEMENTAL FIGURES 
 
Figure S1: 
Study patients and exclusion criteria. 
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Figure S2: 
Censoring of time-to-intensification vs. length of the treatment strategy assessment period. 
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SUPPLEMENTAL TABLES 
 
Table S1:  
List of Read codes used to identify patients with hypertension in the THIN database. 
Descriptions are as provided by the NHS Read code dictionary, version 2. 
 
Read code  Description 
G2...00  Hypertensive disease 
G2...11  BP - hypertensive disease 
G20..00  Essential hypertension 
G20..11  High blood pressure 
G200.00  Malignant essential hypertension 
G201.00  Benign essential hypertension 
G202.00  Systolic hypertension 
G20z.00  Essential hypertension NOS 
G20z.11  Hypertension NOS 
G24..00  Secondary hypertension 
G240.00  Secondary malignant hypertension 
G240000  Secondary malignant renovascular hypertension 
G240z00  Secondary malignant hypertension NOS 
G241.00  Secondary benign hypertension 
G241000  Secondary benign renovascular hypertension 
G241z00  Secondary benign hypertension NOS 
G244.00  Hypertension secondary to endocrine disorders 
G24z.00  Secondary hypertension NOS 
G24z000  Secondary renovascular hypertension NOS 
G24z100  Hypertension secondary to drug 
G24zz00  Secondary hypertension NOS 
G2y..00  Other specified hypertensive disease 
G2z..00  Hypertensive disease NOS 
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Table S2:  
List of anti-hypertensive medications 
 
MEDICATION 
ACEBUTOLOL 
ALISKIREN 
AMILORIDE 
AMLODIPINE 
ATENOLOL 
BAMETHAN 
BENDROFLUMETHIAZIDE 
BENZTHIAZIDE 
BETAXOLOL 
BETHANIDINE 
BISOPROLOL 
BUMETANIDE 
CANDESARTAN 
CAPTOPRIL 
CARTEOLOL 
CARVEDILOL 
CELIPROLOL 
CHLOROTHIAZIDE 
CHLORTALIDONE 
CILAZAPRIL 
CLONIDINE 
CLOPAMIDE 
CYCLOPENTHIAZIDE 
DEBRISOQUINE 
DILTIAZEM 
DOXAZOSIN 
ENALAPRIL 
EPLERENONE 
EPROSARTAN 
ESMOLOL 
ETACRYNIC 
FELODIPINE 
FOSINOPRIL 
FUROSEMIDE 
GUANETHIDINE 
HARMONYL 
HYDRALAZINE 
HYDROCHLOROTHIAZIDE 
HYDROFLUMETHIAZIDE 
IMIDAPRIL 
INDAPAMIDE 
INDORAMIN 
INOSITOL 
IRBESARTAN 
ISOSORBIDE   39
ISRADIPINE 
LABETALOL 
LACIDIPINE 
LERCANIDIPINE 
LISINOPRIL 
LOSARTAN 
MEFRUSIDE 
METHOSERPIDINE 
METHYLDOPA 
METOLAZONE 
METOPROLOL 
MIBEFRADIL 
MINOXIDIL 
MOEXIPRIL 
MOXONIDINE 
NADOLOL 
NEBIVOLOL 
NICARDIPINE 
NIFEDIPINE 
NIMODIPINE 
NISOLDIPINE 
OLMESARTAN 
OXPRENOLOL 
PENBUTOLOL 
PERINDOPRIL 
PHENOXYBENZAMINE 
PINDOLOL 
PIRETANIDE 
POLYTHIAZIDE 
PRAZOSIN 
PROPRANOLOL 
QUINAPRIL 
RAMIPRIL 
RESERPINE 
SOTALOL 
SPIRONOLACTONE 
TELMISARTAN 
TERAZOSIN 
TIMOLOL 
TORASEMIDE 
TRANDOLAPRIL 
TRIAMTERENE 
VALSARTAN 
VERAPAMIL 
XIPAMIDE 
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Table S3:  
List of Read codes associated with baseline medical conditions or acute cardiovascular events. 
Descriptions are as provided by the NHS Read code dictionary, version 2. 
 
Condition 
Read 
Code Description 
CAD  G3...00 Ischaemic heart disease 
CAD  G3...12 Atherosclerotic heart disease 
CAD  G3...13 IHD - Ischaemic heart disease 
CAD  G30..00 Acute myocardial infarction 
CAD  G30..11 Attack - heart 
CAD  G30..12 Coronary thrombosis 
CAD  G30..13 Cardiac rupture following myocardial infarction (MI) 
CAD  G30..14 Heart attack 
CAD  G30..15 MI - acute myocardial infarction 
CAD  G30..16 Thrombosis - coronary 
CAD  G300.00 Acute anterolateral infarction 
CAD  G301.00 Other specified anterior myocardial infarction 
CAD  G301000 Acute anteroapical infarction 
CAD  G301100 Acute anteroseptal infarction 
CAD  G301z00 Anterior myocardial infarction NOS 
CAD  G302.00 Acute inferolateral infarction 
CAD  G303.00 Acute inferoposterior infarction 
CAD  G304.00 Posterior myocardial infarction NOS 
CAD  G305.00 Lateral myocardial infarction NOS 
CAD  G306.00 True posterior myocardial infarction 
CAD  G307.00 Acute subendocardial infarction 
CAD  G307000 Acute non-Q wave infarction 
CAD  G307100 Acute non-ST segment elevation myocardial infarction 
CAD  G308.00 Inferior myocardial infarction NOS 
CAD  G309.00 Acute Q-wave infarct 
CAD  G30A.00 Mural thrombosis 
CAD  G30B.00 Acute posterolateral myocardial infarction 
CAD  G30X.00 Acute transmural myocardial infarction of unspecif site 
CAD  G30X000 Acute ST segment elevation myocardial infarction 
CAD  G30y.00 Other acute myocardial infarction 
CAD  G30y000 Acute atrial infarction 
CAD  G30y200 Acute septal infarction 
CAD  G30yz00 Other acute myocardial infarction NOS 
CAD  G30z.00 Acute myocardial infarction NOS 
CAD  G311.11 Crescendo angina 
CAD  G311.13 Unstable angina 
CAD  G311.14 Angina at rest 
CAD  G311100 Unstable angina 
CAD  G311200 Angina at rest 
CAD  G311300 Refractory angina 
CAD  G311400 Worsening angina   41
Condition 
Read 
Code Description 
CAD  G311500 Acute coronary syndrome 
CAD  G312.00 Coronary thrombosis not resulting in myocardial infarction 
CAD  G31y.00 Other acute and subacute ischaemic heart disease 
CAD  G31y000 Acute coronary insufficiency 
CAD  G32..00 Old myocardial infarction 
CAD  G33..00 Angina pectoris 
CAD  G33z.00 Angina pectoris NOS 
CAD  G33z300 Angina on effort 
CAD  G33z400 Ischaemic chest pain 
CAD  G33z700 Stable angina 
CAD  G33zz00 Angina pectoris NOS 
CAD  G340.00 Coronary atherosclerosis 
CAD  G340.11 Triple vessel disease of the heart 
CAD  G340.12 Coronary artery disease 
CAD  G340000 Single coronary vessel disease 
CAD  G340100 Double coronary vessel disease 
CAD  G343.00 Ischaemic cardiomyopathy 
CAD  G34z000 Asymptomatic coronary heart disease 
CAD  G3z..00 Ischaemic heart disease NOS 
CAD  G70y011 Carotid artery disease 
CAD  G30..17 Silent myocardial infarction 
CAD  G32..11 Healed myocardial infarction 
CAD  G32..12 Personal history of myocardial infarction 
CHF  G211100 Benign hypertensive heart disease with CCF 
CHF  G21z100 Hypertensive heart disease NOS with CCF 
CHF  G232.00 Hypertensive heart&renal dis wth (congestive) heart failure 
CHF  G234.00 Hyperten heart&renal dis+both(congestv)heart and renal fail 
CHF  G58..00 Heart failure 
CHF  G58..11 Cardiac failure 
CHF  G580.00 Congestive heart failure 
CHF  G580.11 Congestive cardiac failure 
CHF  G580.14 Biventricular failure 
CHF  G580000 Acute congestive heart failure 
CHF  G580100 Chronic congestive heart failure 
CHF  G580200 Decompensated cardiac failure 
CHF  G580300 Compensated cardiac failure 
CHF  G581.00 Left ventricular failure 
CHF  G581.12 Pulmonary oedema - acute 
CHF  G581.13 Impaired left ventricular function 
CHF  G581000 Acute left ventricular failure 
CHF  G582.00 Acute heart failure 
CHF  G58z.00 Heart failure NOS 
CHF  G58z.12 Cardiac failure NOS 
CHF  1O1..00 Heart failure confirmed 
CHF  8B29.00 Cardiac failure therapy 
CHF  8CL3.00 Heart failure care plan discussed with patient 
CHF  8H2S.00 Admit heart failure emergency 
CHF  G554000 Congestive cardiomyopathy 
CVA  G6...00 Cerebrovascular disease 
CVA  G60..00 Subarachnoid haemorrhage   42
Condition 
Read 
Code Description 
CVA  G61..00 Intracerebral haemorrhage 
CVA  G61..11
CVA - cerebrovascular accid due to intracerebral 
haemorrhage 
CVA  G61..12 Stroke due to intracerebral haemorrhage 
CVA  G610.00 Cortical haemorrhage 
CVA  G611.00 Internal capsule haemorrhage 
CVA  G612.00 Basal nucleus haemorrhage 
CVA  G613.00 Cerebellar haemorrhage 
CVA  G614.00 Pontine haemorrhage 
CVA  G615.00 Bulbar haemorrhage 
CVA  G616.00 External capsule haemorrhage 
CVA  G617.00 Intracerebral haemorrhage, intraventricular 
CVA  G618.00 Intracerebral haemorrhage, multiple localized 
CVA  G61X.00 Intracerebral haemorrhage in hemisphere, unspecified 
CVA  G61X000 Left sided intracerebral haemorrhage, unspecified 
CVA  G61X100 Right sided intracerebral haemorrhage, unspecified 
CVA  G61z.00 Intracerebral haemorrhage NOS 
CVA  G63..00 Precerebral arterial occlusion 
CVA  G63..11 Infarction - precerebral 
CVA  G630.00 Basilar artery occlusion 
CVA  G631.00 Carotid artery occlusion 
CVA  G631.12 Thrombosis, carotid artery 
CVA  G632.00 Vertebral artery occlusion 
CVA  G63y.00 Other precerebral artery occlusion 
CVA  G63y000 Cerebral infarct due to thrombosis of precerebral arteries 
CVA  G63y100 Cerebral infarction due to embolism of precerebral arteries 
CVA  G64..00 Cerebral arterial occlusion 
CVA  G64..11 CVA - cerebral artery occlusion 
CVA  G64..12 Infarction - cerebral 
CVA  G64..13 Stroke due to cerebral arterial occlusion 
CVA  G640.00 Cerebral thrombosis 
CVA  G640000 Cerebral infarction due to thrombosis of cerebral arteries 
CVA  G64z.00 Cerebral infarction NOS 
CVA  G64z.11 Brainstem infarction NOS 
CVA  G64z.12 Cerebellar infarction 
CVA  G64z000 Brainstem infarction 
CVA  G64z100 Wallenberg syndrome 
CVA  G64z111 Lateral medullary syndrome 
CVA  G64z200 Left sided cerebral infarction 
CVA  G64z300 Right sided cerebral infarction 
CVA  G64z400 Infarction of basal ganglia 
CVA  G65..00 Transient cerebral ischaemia 
CVA  G65..12 Transient ischaemic attack 
CVA  G65zz00 Transient cerebral ischaemia NOS 
CVA  G66..00 Stroke and cerebrovascular accident unspecified 
CVA  G66..11 CVA unspecified 
CVA  G66..12 Stroke unspecified 
CVA  G66..13 CVA - Cerebrovascular accident unspecified 
CVA  G660.00 Middle cerebral artery syndrome 
CVA  G661.00 Anterior cerebral artery syndrome   43
Condition 
Read 
Code Description 
CVA  G662.00 Posterior cerebral artery syndrome 
CVA  G663.00 Brain stem stroke syndrome 
CVA  G664.00 Cerebellar stroke syndrome 
CVA  G665.00 Pure motor lacunar syndrome 
CVA  G666.00 Pure sensory lacunar syndrome 
CVA  G667.00 Left sided CVA 
CVA  G668.00 Right sided CVA 
CVA  G6W..00 Cereb infarct due unsp occlus/stenos precerebr arteries 
CVA  G6X..00 Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs 
CVA  G6z..00 Cerebrovascular disease NOS 
CVA  F11x200 Cerebral degeneration due to cerebrovascular disease 
CVA  G600.00 Ruptured berry aneurysm 
CVA  G63..12 Stenosis of precerebral arteries 
CVA  G633.00 Multiple and bilateral precerebral arterial occlusion 
CVA  G63z.00 Precerebral artery occlusion NOS 
CVA  G641000 Cerebral infarction due to embolism of cerebral arteries 
CVA  G65y.00 Other transient cerebral ischaemia 
CVA  G67..00 Other cerebrovascular disease 
CVA  G671.00 Generalised ischaemic cerebrovascular disease NOS 
CVA  G671z00 Generalised ischaemic cerebrovascular disease NOS 
CVA  G677400 Occlusion??? of multiple and bilat cerebral arteries 
CVA  G67y.00 Other cerebrovascular disease OS 
CVA  G67z.00 Other cerebrovascular disease NOS 
CVA  G68..00 Late effects of cerebrovascular disease 
CVA  G6y..00 Other specified cerebrovascular disease 
CVA  Gyu6.00 Cerebrovascular diseases 
CVA  Gyu6500 Occlusion and stenosis of other precerebral arteries 
CVA  Gyu6600 Occlusion and stenosis of other cerebral arteries 
CVA  Gyu6700 Other specified cerebrovascular diseases 
CVA  Gyu6D00 Sequelae/other  unspecified cerebrovascular diseases 
CVA  G68W.00 Sequelae/other  unspecified cerebrovascular diseases 
PVD  G631.11 Stenosis, carotid artery 
PVD  G634.00 Carotid artery stenosis 
PVD  G650.11 Insufficiency - basilar artery 
PVD  G651000 Vertebro-basilar artery syndrome 
PVD  G656.00 Vertebrobasilar insufficiency 
PVD  G65z.00 Transient cerebral ischaemia NOS 
PVD  G70z.00 Arteriosclerotic vascular disease NOS 
PVD  G73..00 Other peripheral vascular disease 
PVD  G73..11 Peripheral ischaemic vascular disease 
PVD  G73..12 Ischaemia of legs 
PVD  G73..13 Peripheral ischaemia 
PVD  G732.00 Peripheral gangrene 
PVD  G732000 Gangrene of toe 
PVD  G732100 Gangrene of foot 
PVD  G73yz00 Other specified peripheral vascular disease NOS 
PVD  G73z.00 Peripheral vascular disease NOS 
PVD  G73z000 Intermittent claudication 
PVD  G73z011 Claudication 
PVD  G73zz00 Peripheral vascular disease NOS   44
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Read 
Code Description 
  
Diabetes  1434 H/O: diabetes mellitus 
Diabetes  2BBk.00 O/E - right eye stable treated prolif diabetic retinopathy 
Diabetes  2BBL.00 O/E - diabetic maculopathy present both eyes 
Diabetes  2BBl.00 O/E - left eye stable treated prolif diabetic retinopathy 
Diabetes  2BBP.00 O/E - right eye background diabetic retinopathy 
Diabetes  2BBQ.00 O/E - left eye background diabetic retinopathy 
Diabetes  2BBR.00 O/E - right eye preproliferative diabetic retinopathy 
Diabetes  2BBS.00 O/E - left eye preproliferative diabetic retinopathy 
Diabetes  2BBV.00 O/E - left eye proliferative diabetic retinopathy 
Diabetes  66A5.00 Diabetic on insulin 
Diabetes  66AI.00 Diabetic - good control 
Diabetes  66AJ.00 Diabetic - poor control 
Diabetes  66AJ.11 Unstable diabetes 
Diabetes  66AJz00 Diabetic - poor control NOS 
Diabetes  66AK.00 Diabetic - cooperative patient 
Diabetes  66AS.00 Diabetic annual review 
Diabetes  66AV.00 Diabetic on insulin and oral treatment 
Diabetes  8A13.00 Diabetic stabilisation 
Diabetes  8BL2.00 Patient on maximal tolerated therapy for diabetes 
Diabetes  8H2J.00 Admit diabetic emergency 
Diabetes  C10..00 Diabetes mellitus 
Diabetes  C100.00 Diabetes mellitus with no mention of complication 
Diabetes  C100000 Diabetes mellitus, juvenile type, no mention of complication 
Diabetes  C100011 Insulin dependent diabetes mellitus 
Diabetes  C100100 Diabetes mellitus, adult onset, no mention of complication 
Diabetes  C100111 Maturity onset diabetes 
Diabetes  C100112 Non-insulin dependent diabetes mellitus 
Diabetes  C100z00 Diabetes mellitus NOS with no mention of complication 
Diabetes  C101.00 Diabetes mellitus with ketoacidosis 
Diabetes  C101100 Diabetes mellitus, adult onset, with ketoacidosis 
Diabetes  C101z00 Diabetes mellitus NOS with ketoacidosis 
Diabetes  C102.00 Diabetes mellitus with hyperosmolar coma 
Diabetes  C102100 Diabetes mellitus, adult onset, with hyperosmolar coma 
Diabetes  C102z00 Diabetes mellitus NOS with hyperosmolar coma 
Diabetes  C103.00 Diabetes mellitus with ketoacidotic coma 
Diabetes  C103000 Diabetes mellitus, juvenile type, with ketoacidotic coma 
Diabetes  C103z00 Diabetes mellitus NOS with ketoacidotic coma 
Diabetes  C104.11 Diabetic nephropathy 
Diabetes  C104000 Diabetes mellitus, juvenile type, with renal manifestation 
Diabetes  C104y00 Other specified diabetes mellitus with renal complications 
Diabetes  C104z00 Diabetes mellitis with nephropathy NOS 
Diabetes  C105.00 Diabetes mellitus with ophthalmic manifestation 
Diabetes  C105100 Diabetes mellitus, adult onset,  ophthalmic manifestation 
Diabetes  C105y00 Other specified diabetes mellitus with ophthalmic complicatn 
Diabetes  C105z00 Diabetes mellitus NOS with ophthalmic manifestation 
Diabetes  C106.00 Diabetes mellitus with neurological manifestation 
Diabetes  C106.11 Diabetic amyotrophy 
Diabetes  C106.12 Diabetes mellitus with neuropathy 
Diabetes  C106100 Diabetes mellitus, adult onset,  neurological manifestation   45
Condition 
Read 
Code Description 
Diabetes  C106y00 Other specified diabetes mellitus with neurological comps 
Diabetes  C106z00 Diabetes mellitus NOS with neurological manifestation 
Diabetes  C107.00 Diabetes mellitus with peripheral circulatory disorder 
Diabetes  C107.11 Diabetes mellitus with gangrene 
Diabetes  C107.12 Diabetes with gangrene 
Diabetes  C107000 Diabetes mellitus, juvenile ??? circulatory disorder 
Diabetes  C107200 Diabetes mellitus, adult with gangrene 
Diabetes  C107300 IDDM with peripheral circulatory disorder 
Diabetes  C107400 NIDDM with peripheral circulatory disorder 
Diabetes  C107z00 Diabetes mellitus NOS with peripheral circulatory disorder 
Diabetes  C108.00 Insulin dependent diabetes mellitus 
Diabetes  C108.11 IDDM-Insulin dependent diabetes mellitus 
Diabetes  C108.12 Type 1 diabetes mellitus 
Diabetes  C108.13 Type I diabetes mellitus 
Diabetes  C108000 Insulin-dependent diabetes mellitus with renal complications 
Diabetes  C108011 Type I diabetes mellitus with renal complications 
Diabetes  C108012 Type 1 diabetes mellitus with renal complications 
Diabetes  C108100 Insulin-dependent diabetes mellitus with ophthalmic comps 
Diabetes  C108212 Type 1 diabetes mellitus with neurological complications 
Diabetes  C108400 Unstable insulin dependent diabetes mellitus 
Diabetes  C108500 Insulin dependent diabetes mellitus with ulcer 
Diabetes  C108511 Type I diabetes mellitus with ulcer 
Diabetes  C108700 Insulin dependent diabetes mellitus with retinopathy 
Diabetes  C108711 Type I diabetes mellitus with retinopathy 
Diabetes  C108712 Type 1 diabetes mellitus with retinopathy 
Diabetes  C108800 Insulin dependent diabetes mellitus - poor control 
Diabetes  C108811 Type I diabetes mellitus - poor control 
Diabetes  C108B00 Insulin dependent diabetes mellitus with mononeuropathy 
Diabetes  C108B11 Type I diabetes mellitus with mononeuropathy 
Diabetes  C108C00 Insulin dependent diabetes mellitus with polyneuropathy 
Diabetes  C108D00 Insulin dependent diabetes mellitus with nephropathy 
Diabetes  C108D11 Type I diabetes mellitus with nephropathy 
Diabetes  C108E00 Insulin dependent diabetes mellitus with hypoglycaemic coma 
Diabetes  C108E11 Type I diabetes mellitus with hypoglycaemic coma 
Diabetes  C108E12 Type 1 diabetes mellitus with hypoglycaemic coma 
Diabetes  C108F00 Insulin dependent diabetes mellitus with diabetic cataract 
Diabetes  C108F11 Type I diabetes mellitus with diabetic cataract 
Diabetes  C108G00 Insulin dependent diab mell with peripheral angiopathy 
Diabetes  C108H00 Insulin dependent diabetes mellitus with arthropathy 
Diabetes  C109.00 Non-insulin-dependent diabetes mellitus 
Diabetes  C109.11 NIDDM - Non-insulin dependent diabetes mellitus 
Diabetes  C109.12 Type 2 diabetes mellitus 
Diabetes  C109.13 Type II diabetes mellitus 
Diabetes  C109000 Non-insulin-dependent diabetes mellitus with renal comps 
Diabetes  C109011 Type II diabetes mellitus with renal complications 
Diabetes  C109012 Type 2 diabetes mellitus with renal complications 
Diabetes  C109200 Non-insulin-dependent diabetes mellitus with neuro comps 
Diabetes  C109212 Type 2 diabetes mellitus with neurological complications 
Diabetes  C109400 Non-insulin dependent diabetes mellitus with ulcer 
Diabetes  C109411 Type II diabetes mellitus with ulcer   46
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Read 
Code Description 
Diabetes  C109500 Non-insulin dependent diabetes mellitus with gangrene 
Diabetes  C109600 Non-insulin-dependent diabetes mellitus with retinopathy 
Diabetes  C109611 Type II diabetes mellitus with retinopathy 
Diabetes  C109612 Type 2 diabetes mellitus with retinopathy 
Diabetes  C109700 Non-insulin dependant diabetes mellitus - poor control 
Diabetes  C109711 Type II diabetes mellitus - poor control 
Diabetes  C109712 Type 2 diabetes mellitus - poor control 
Diabetes  C109900 Non-insulin-dependent diabetes mellitus without complication 
Diabetes  C109B00 Non-insulin dependent diabetes mellitus with polyneuropathy 
Diabetes  C109B11 Type II diabetes mellitus with polyneuropathy 
Diabetes  C109C00 Non-insulin dependent diabetes mellitus with nephropathy 
Diabetes  C109C11 Type II diabetes mellitus with nephropathy 
Diabetes  C109C12 Type 2 diabetes mellitus with nephropathy 
Diabetes  C109D00 Non-insulin dependent diabetes mellitus with hypoglyca coma 
Diabetes  C109E00 Non-insulin depend diabetes mellitus with diabetic cataract 
Diabetes  C109E11 Type II diabetes mellitus with diabetic cataract 
Diabetes  C109E12 Type 2 diabetes mellitus with diabetic cataract 
Diabetes  C109F11 Type II diabetes mellitus with peripheral angiopathy 
Diabetes  C109G00 Non-insulin dependent diabetes mellitus with arthropathy 
Diabetes  C109H00 Non-insulin dependent d m with neuropathic arthropathy 
Diabetes  C109H11 Type II diabetes mellitus with neuropathic arthropathy 
Diabetes  C109H12 Type 2 diabetes mellitus with neuropathic arthropathy 
Diabetes  C109J00 Insulin treated Type 2 diabetes mellitus 
Diabetes  C109J11 Insulin treated non-insulin dependent diabetes mellitus 
Diabetes  C109J12 Insulin treated Type II diabetes mellitus 
Diabetes  C109K00 Hyperosmolar non-ketotic state in type 2 diabetes mellitus 
Diabetes  C10A.00 Malnutrition-related diabetes mellitus 
Diabetes  C10A100 Malnutrition-related diabetes mellitus with ketoacidosis 
Diabetes  C10B000 Steroid induced diabetes mellitus without complication 
Diabetes  C10D.00 Diabetes mellitus autosomal dominant type 2 
Diabetes  C10E.00 Type 1 diabetes mellitus 
Diabetes  C10E.11 Type I diabetes mellitus 
Diabetes  C10E.12 Insulin dependent diabetes mellitus 
Diabetes  C10E000 Type 1 diabetes mellitus with renal complications 
Diabetes  C10E100 Type 1 diabetes mellitus with ophthalmic complications 
Diabetes  C10E200 Type 1 diabetes mellitus with neurological complications 
Diabetes  C10E400 Unstable type 1 diabetes mellitus 
Diabetes  C10E412 Unstable insulin dependent diabetes mellitus 
Diabetes  C10E500 Type 1 diabetes mellitus with ulcer 
Diabetes  C10E600 Type 1 diabetes mellitus with gangrene 
Diabetes  C10E800 Type 1 diabetes mellitus - poor control 
Diabetes  C10E900 Type 1 diabetes mellitus maturity onset 
Diabetes  C10EA00 Type 1 diabetes mellitus without complication 
Diabetes  C10ED00 Type 1 diabetes mellitus with nephropathy 
Diabetes  C10EE00 Type 1 diabetes mellitus with hypoglycaemic coma 
Diabetes  C10EF00 Type 1 diabetes mellitus with diabetic cataract 
Diabetes  C10EK00 Type 1 diabetes mellitus with persistent proteinuria 
Diabetes  C10EL00 Type 1 diabetes mellitus with persistent microalbuminuria 
Diabetes  C10EM00 Type 1 diabetes mellitus with ketoacidosis 
Diabetes  C10EM11 Type I diabetes mellitus with ketoacidosis   47
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Read 
Code Description 
Diabetes  C10EN00 Type 1 diabetes mellitus with ketoacidotic coma 
Diabetes  C10EQ00 Type 1 diabetes mellitus with gastroparesis 
Diabetes  C10F.00 Type 2 diabetes mellitus 
Diabetes  C10F.11 Type II diabetes mellitus 
Diabetes  C10F000 Type 2 diabetes mellitus with renal complications 
Diabetes  C10F011 Type II diabetes mellitus with renal complications 
Diabetes  C10F100 Type 2 diabetes mellitus with ophthalmic complications 
Diabetes  C10F200 Type 2 diabetes mellitus with neurological complications 
Diabetes  C10F400 Type 2 diabetes mellitus with ulcer 
Diabetes  C10F500 Type 2 diabetes mellitus with gangrene 
Diabetes  C10F600 Type 2 diabetes mellitus with retinopathy 
Diabetes  C10F611 Type II diabetes mellitus with retinopathy 
Diabetes  C10F700 Type 2 diabetes mellitus - poor control 
Diabetes  C10F711 Type II diabetes mellitus - poor control 
Diabetes  C10F900 Type 2 diabetes mellitus without complication 
Diabetes  C10FA00 Type 2 diabetes mellitus with mononeuropathy 
Diabetes  C10FB00 Type 2 diabetes mellitus with polyneuropathy 
Diabetes  C10FC00 Type 2 diabetes mellitus with nephropathy 
Diabetes  C10FD00 Type 2 diabetes mellitus with hypoglycaemic coma 
Diabetes  C10FE00 Type 2 diabetes mellitus with diabetic cataract 
Diabetes  C10FF00 Type 2 diabetes mellitus with peripheral angiopathy 
Diabetes  C10FG00 Type 2 diabetes mellitus with arthropathy 
Diabetes  C10FH00 Type 2 diabetes mellitus with neuropathic arthropathy 
Diabetes  C10FJ00 Insulin treated Type 2 diabetes mellitus 
Diabetes  C10FJ11 Insulin treated Type II diabetes mellitus 
Diabetes  C10FL00 Type 2 diabetes mellitus with persistent proteinuria 
Diabetes  C10FL11 Type II diabetes mellitus with persistent proteinuria 
Diabetes  C10FM00 Type 2 diabetes mellitus with persistent microalbuminuria 
Diabetes  C10FN00 Type 2 diabetes mellitus with ketoacidosis 
Diabetes  C10FP00 Type 2 diabetes mellitus with ketoacidotic coma 
Diabetes  C10FR00 Type 2 diabetes mellitus with gastroparesis 
Diabetes  C10G.00 Secondary pancreatic diabetes mellitus 
Diabetes  C10H.00 Diabetes mellitus induced by non-steroid drugs 
Diabetes  C10M.00 Lipoatrophic diabetes mellitus 
Diabetes  C10N.00 Secondary diabetes mellitus 
Diabetes  C10y.00 Diabetes mellitus with other specified manifestation 
Diabetes  C10y100 Diabetes mellitus, adult,  other specified manifestation 
Diabetes  C10yy00 Other specified diabetes mellitus with other spec comps 
Diabetes  C10z.00 Diabetes mellitus with unspecified complication 
Diabetes  C10z100 Diabetes mellitus, adult onset,  unspecified complication 
Diabetes  C10zz00 Diabetes mellitus NOS with unspecified complication 
Diabetes  Cyu2.00 [X]Diabetes mellitus 
Diabetes  F372.11 Diabetic polyneuropathy 
Diabetes  F372.12 Diabetic neuropathy 
Diabetes  F374z00 Polyneuropathy in disease NOS 
Diabetes  F381300 Myasthenic syndrome due to diabetic amyotrophy 
Diabetes  F381311 Diabetic amyotrophy 
Diabetes  F3y0.00 Diabetic mononeuropathy 
Diabetes  F420.00 Diabetic retinopathy 
Diabetes  F420100 Proliferative diabetic retinopathy   48
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Read 
Code Description 
Diabetes  F420200 Preproliferative diabetic retinopathy 
Diabetes  F420300 Advanced diabetic maculopathy 
Diabetes  F420400 Diabetic maculopathy 
Diabetes  F420600 Non proliferative diabetic retinopathy 
Diabetes  F420700 High risk proliferative diabetic retinopathy 
Diabetes  F420800 High risk non proliferative diabetic retinopathy 
Diabetes  F420z00 Diabetic retinopathy NOS 
Diabetes  F464000 Diabetic cataract 
Diabetes  G73y000 Diabetic peripheral angiopathy 
Diabetes  L180500 Pre-existing diabetes mellitus, insulin-dependent 
Diabetes  L180600 Pre-existing diabetes mellitus, non-insulin-dependent 
Diabetes  L180X00 Pre-existing diabetes mellitus, unspecified 
  
Chronic kidney disease  14V2.00 H/O: renal dialysis 
Chronic kidney disease  14V2.11 H/O: kidney dialysis 
Chronic kidney disease  1Z12.00 Chronic kidney disease stage 3 
Chronic kidney disease  1Z13.00 Chronic kidney disease stage 4 
Chronic kidney disease  1Z14.00 Chronic kidney disease stage 5 
Chronic kidney disease  1Z15.00 Chronic kidney disease stage 3A 
Chronic kidney disease  1Z16.00 Chronic kidney disease stage 3B 
Chronic kidney disease  1Z1B.00 Chronic kidney disease stage 3 with proteinuria 
Chronic kidney disease  1Z1C.00 Chronic kidney disease stage 3 without proteinuria 
Chronic kidney disease  1Z1D.00 Chronic kidney disease stage 3A with proteinuria 
Chronic kidney disease  1Z1E.00 Chronic kidney disease stage 3A without proteinuria 
Chronic kidney disease  1Z1F.00 Chronic kidney disease stage 3B with proteinuria 
Chronic kidney disease  1Z1G.00 Chronic kidney disease stage 3B without proteinuria 
Chronic kidney disease  1Z1H.00 Chronic kidney disease stage 4 with proteinuria 
Chronic kidney disease  1Z1J.00 Chronic kidney disease stage 4 without proteinuria 
Chronic kidney disease  1Z1K.00 Chronic kidney disease stage 5 with proteinuria 
Chronic kidney disease  1Z1L.00 Chronic kidney disease stage 5 without proteinuria 
Chronic kidney disease  7A60600 Creation of graft fistula for dialysis 
Chronic kidney disease  7A61900 Ligation of arteriovenous dialysis fistula 
Chronic kidney disease  7L1A.11 Dialysis for renal failure 
Chronic kidney disease  7L1A000 Renal dialysis 
Chronic kidney disease  7L1A100 Peritoneal dialysis 
Chronic kidney disease  7L1A200 Haemodialysis NEC 
Chronic kidney disease  7L1A400 Automated peritoneal dialysis 
Chronic kidney disease  7L1A500 Continuous ambulatory peritoneal dialysis 
Chronic kidney disease  7L1A600 Peritoneal dialysis NEC 
Chronic kidney disease  7L1B.11 Placement ambulatory dialysis apparatus - compens renal fail 
Chronic kidney disease  7L1B000 Insertion of ambulatory peritoneal dialysis catheter 
Chronic kidney disease  7L1B100 Removal of ambulatory peritoneal dialysis catheter 
Chronic kidney disease  7L1C000 Insertion of temporary peritoneal dialysis catheter 
Chronic kidney disease  8882 Intestinal dialysis 
Chronic kidney disease  K05..12 End stage renal failure 
Chronic kidney disease  K050.00 End stage renal failure 
Chronic kidney disease  K0D..00 End-stage renal disease 
Chronic kidney disease  SP01500 Mechanical complication of dialysis catheter 
Chronic kidney disease  SP05613 [X] Peritoneal dialysis associated peritonitis 
Chronic kidney disease  SP07G00 Stenosis of arteriovenous dialysis fistula   49
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Read 
Code Description 
Chronic kidney disease  TB11.00 Kidney dialysis with complication, without blame 
Chronic kidney disease  Z919100 Priming haemodialysis lines 
Chronic kidney disease  Z919300 Reversing haemodialysis lines 
Chronic kidney disease  Z91A.00 Peritoneal dialysis bag procedure 
Chronic kidney disease  ZV45100 [V]Renal dialysis status 
Chronic kidney disease  ZV56.00 [V]Aftercare involving intermittent dialysis 
Chronic kidney disease  ZV56011 [V]Aftercare involving renal dialysis NOS 
Chronic kidney disease  ZV56100 [V]Preparatory care for dialysis 
Chronic kidney disease  ZV56y11 [V]Aftercare involving peritoneal dialysis 
Chronic kidney disease  ZVu3G00 [X]Other dialysis 
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Table S4: 
Antihypertensive treatment strategy and overall mortality risk.  
 
Characteristic 
n (%) or 
mean (SD)
   
Hazard 
Ratio     p-value     95% CI 
Minimum systolic intensification 
threshold, mmHg      
   130-139  10853 (13.4) 0.987 0.80  0.895-1.089
   140-149  18646 (23.0) 1.000 --  --
   150-159  19724 (24.3) 1.052 0.22  0.970-1.140
   160-169  16177 (19.9) 1.256 <0.0001  1.153-1.368
   170-179  8253 (10.2) 1.424 <0.0001  1.283-1.581
   180+  7525 (9.3) 1.690 <0.0001  1.526-1.872
Mean time to intensification, 
quintiles, months       
   0-1.406  16233 (20.0) 1.000 --  --
   1.407-4.646  16238 (20.0) 1.112 0.0088  1.027-1.203
   4.647-8.684  16236 (20.0) 1.235 <0.0001  1.139-1.339
   8.685-15.350  16238 (20.0) 1.196 <0.0001  1.099-1.302
   15.351+  16233 (20.0) 1.297 <0.0001  1.190-1.415
Mean time to follow-up after 
intensification, quintiles, months     
   0-0.723  16652 (20.5) 1.023 0.55  0.948-1.104
   0.724-1.018  14747 (18.2) 1.000 --  --
   1.019-1.544  17110 (21.1) 1.005 0.90  0.931-1.085
   1.545-2.694  16577 (20.4) 1.053 0.18  0.976-1.137
   2.695+  16092 (19.8) 1.210 <0.0001  1.125-1.301
Mean SBP elevation over 
intensification thresold, mmHg (%)*     
   1-9  43576 (53.7) 1.000 --  --
   10-19  28627 (35.3) 1.119 0.0008  1.048-1.195
   20-29  7521 (9.3) 1.311 <0.0001  1.192-1.443
   30-39  1301 (1.6) 1.576 <0.0001  1.339-1.854
   40-49  153 (0.2) 1.975 0.0006  1.336-2.920
      
Medication possession ratio  0.861 (0.192) 0.919 0.14  0.822-1.028
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Table S5: 
Intensification Thresholds and Composite Outcome Risk under Liberalized Inclusion Criteria. 
 
 M i n i m u m   s y s t o l i c   i n t e n s i f i c a t i o n   t h r e s h o l d ,   m m H g  
  130-139  140-149  150-159  160-169  170-179  180+ 
Number of 
patients (%)  42343 (12.9)  71820 (21.8) 79630 (24.2) 66204 (20.1)  36926 (11.2) 32568 (9.9)
Hazard ratio  0.923  1.000 1.073 1.202  1.327 1.678
p-value  <0.0001  -- <0.0001 <0.0001  <0.0001 <0.0001
95% CI  0.888-0.959  -- 1.041-1.106 1.166-1.240 1 . 2 8 3 - 1 . 3 7 31 . 6 2 4 - 1 . 7 3 4
 